Serveur d'exploration sur les relations entre la France et l'Australie

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor fidarestat: Stereospecific interaction between the enzyme and a cyclic imide type inhibitor

Identifieur interne : 00AC48 ( Main/Exploration ); précédent : 00AC47; suivant : 00AC49

High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor fidarestat: Stereospecific interaction between the enzyme and a cyclic imide type inhibitor

Auteurs : Ossama El-Kabbani [Australie, Japon, Suisse, France] ; Connie Darmanin ; Mitsuru Oka ; Clemens Schulze-Briese ; Takashi Tomizaki ; Isabelle Hazemann ; Andre Mitschler ; Alberto Podjarny

Source :

RBID : Pascal:05-0124639

Descripteurs français

English descriptors

Abstract

Structure determinations of human aldose reductase holoenzyme in complex with the 2S4R-, 2R4S- and 2R4R-isomers of the potent inhibitor Fidarestat ((2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamide) were carried out in order to elucidate the binding modes responsible for the differences in their inhibitory potencies. In the complex structure with the 2R4S-isomer the cyclic imide moiety formed hydrogen bonds with the side-chains of Trplll, Tyr48 and His110. In the attempt to determine the complex structure with the least potent 2R4R-isomer this ligand was not observed, and instead, the active site was simultaneously occupied by two citrate molecules (occupancies of 60% and 40%). In the case of 2S4R, the active site was occupied by a citrate molecule which anchors the 2S4R-isomer from its carbamoyl group. The structures of the complexes suggest that the differences in the interactions between the cyclic imide rings and carbamoyl groups of the compounds with residues His110, Trplll, Trp219 and Cys298 account for differences in their inhibitory potencies.


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor fidarestat: Stereospecific interaction between the enzyme and a cyclic imide type inhibitor</title>
<author>
<name sortKey="El Kabbani, Ossama" sort="El Kabbani, Ossama" uniqKey="El Kabbani O" first="Ossama" last="El-Kabbani">Ossama El-Kabbani</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Medicinal Chemistry, Victorian College of Pharmacy, Monash University (Parkville Campus), 381 Royal Parade</s1>
<s2>Parkville, Vic 3052</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Parkville, Vic 3052</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Sanwa Kagaku Kenkyusyo Company, Ltd., 363, Shiosaki, Hokusei-cho</s1>
<s2>Inabe-gun, Mie 511-0406</s2>
<s3>JPN</s3>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Inabe-gun, Mie 511-0406</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Swiss Light Source at PSI</s1>
<s2>5232 Villigen</s2>
<s3>CHE</s3>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>Swiss Light Source at PSI</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>UPR de Biologie Structurale, IGBMC, CNRS INSERM ULP, 1 rue Laurent Fries, B.P. 163</s1>
<s2>67404 Illkirch</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<wicri:noRegion>67404 Illkirch</wicri:noRegion>
<wicri:noRegion>B.P. 163</wicri:noRegion>
<wicri:noRegion>67404 Illkirch</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Darmanin, Connie" sort="Darmanin, Connie" uniqKey="Darmanin C" first="Connie" last="Darmanin">Connie Darmanin</name>
</author>
<author>
<name sortKey="Oka, Mitsuru" sort="Oka, Mitsuru" uniqKey="Oka M" first="Mitsuru" last="Oka">Mitsuru Oka</name>
</author>
<author>
<name sortKey="Schulze Briese, Clemens" sort="Schulze Briese, Clemens" uniqKey="Schulze Briese C" first="Clemens" last="Schulze-Briese">Clemens Schulze-Briese</name>
</author>
<author>
<name sortKey="Tomizaki, Takashi" sort="Tomizaki, Takashi" uniqKey="Tomizaki T" first="Takashi" last="Tomizaki">Takashi Tomizaki</name>
</author>
<author>
<name sortKey="Hazemann, Isabelle" sort="Hazemann, Isabelle" uniqKey="Hazemann I" first="Isabelle" last="Hazemann">Isabelle Hazemann</name>
</author>
<author>
<name sortKey="Mitschler, Andre" sort="Mitschler, Andre" uniqKey="Mitschler A" first="Andre" last="Mitschler">Andre Mitschler</name>
</author>
<author>
<name sortKey="Podjarny, Alberto" sort="Podjarny, Alberto" uniqKey="Podjarny A" first="Alberto" last="Podjarny">Alberto Podjarny</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">05-0124639</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 05-0124639 INIST</idno>
<idno type="RBID">Pascal:05-0124639</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">004A84</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001619</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">004B20</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">004B20</idno>
<idno type="wicri:doubleKey">0022-2623:2004:El Kabbani O:high:resolution:structures</idno>
<idno type="wicri:Area/Main/Merge">00B947</idno>
<idno type="wicri:Area/Main/Curation">00AC48</idno>
<idno type="wicri:Area/Main/Exploration">00AC48</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor fidarestat: Stereospecific interaction between the enzyme and a cyclic imide type inhibitor</title>
<author>
<name sortKey="El Kabbani, Ossama" sort="El Kabbani, Ossama" uniqKey="El Kabbani O" first="Ossama" last="El-Kabbani">Ossama El-Kabbani</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Medicinal Chemistry, Victorian College of Pharmacy, Monash University (Parkville Campus), 381 Royal Parade</s1>
<s2>Parkville, Vic 3052</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Parkville, Vic 3052</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Sanwa Kagaku Kenkyusyo Company, Ltd., 363, Shiosaki, Hokusei-cho</s1>
<s2>Inabe-gun, Mie 511-0406</s2>
<s3>JPN</s3>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Inabe-gun, Mie 511-0406</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Swiss Light Source at PSI</s1>
<s2>5232 Villigen</s2>
<s3>CHE</s3>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>Swiss Light Source at PSI</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>UPR de Biologie Structurale, IGBMC, CNRS INSERM ULP, 1 rue Laurent Fries, B.P. 163</s1>
<s2>67404 Illkirch</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<wicri:noRegion>67404 Illkirch</wicri:noRegion>
<wicri:noRegion>B.P. 163</wicri:noRegion>
<wicri:noRegion>67404 Illkirch</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Darmanin, Connie" sort="Darmanin, Connie" uniqKey="Darmanin C" first="Connie" last="Darmanin">Connie Darmanin</name>
</author>
<author>
<name sortKey="Oka, Mitsuru" sort="Oka, Mitsuru" uniqKey="Oka M" first="Mitsuru" last="Oka">Mitsuru Oka</name>
</author>
<author>
<name sortKey="Schulze Briese, Clemens" sort="Schulze Briese, Clemens" uniqKey="Schulze Briese C" first="Clemens" last="Schulze-Briese">Clemens Schulze-Briese</name>
</author>
<author>
<name sortKey="Tomizaki, Takashi" sort="Tomizaki, Takashi" uniqKey="Tomizaki T" first="Takashi" last="Tomizaki">Takashi Tomizaki</name>
</author>
<author>
<name sortKey="Hazemann, Isabelle" sort="Hazemann, Isabelle" uniqKey="Hazemann I" first="Isabelle" last="Hazemann">Isabelle Hazemann</name>
</author>
<author>
<name sortKey="Mitschler, Andre" sort="Mitschler, Andre" uniqKey="Mitschler A" first="Andre" last="Mitschler">Andre Mitschler</name>
</author>
<author>
<name sortKey="Podjarny, Alberto" sort="Podjarny, Alberto" uniqKey="Podjarny A" first="Alberto" last="Podjarny">Alberto Podjarny</name>
</author>
</analytic>
<series>
<title level="j" type="main">Journal of medicinal chemistry : (Print)</title>
<title level="j" type="abbreviated">J. med. chem. : (Print)</title>
<idno type="ISSN">0022-2623</idno>
<imprint>
<date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Journal of medicinal chemistry : (Print)</title>
<title level="j" type="abbreviated">J. med. chem. : (Print)</title>
<idno type="ISSN">0022-2623</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Aldehyde reductase</term>
<term>Enzyme inhibitor</term>
<term>Fidarestat</term>
<term>Human</term>
<term>Imide</term>
<term>Modeling</term>
<term>Molecular model</term>
<term>Oxygen nitrogen heterocycle</term>
<term>Spiran</term>
<term>Stereoisomer</term>
<term>Structural analysis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Analyse structurale</term>
<term>Inhibiteur enzyme</term>
<term>Aldehyde reductase</term>
<term>Homme</term>
<term>Modélisation</term>
<term>Modèle moléculaire</term>
<term>Fidarestat</term>
<term>Stéréoisomère</term>
<term>Imide</term>
<term>Spirane</term>
<term>Hétérocycle oxygène azote</term>
<term>Spiro[1-benzopyrane-4:4p-imidazolidine-2-carboxamide] dérivé</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Structure determinations of human aldose reductase holoenzyme in complex with the 2S4R-, 2R4S- and 2R4R-isomers of the potent inhibitor Fidarestat ((2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamide) were carried out in order to elucidate the binding modes responsible for the differences in their inhibitory potencies. In the complex structure with the 2R4S-isomer the cyclic imide moiety formed hydrogen bonds with the side-chains of Trplll, Tyr48 and His110. In the attempt to determine the complex structure with the least potent 2R4R-isomer this ligand was not observed, and instead, the active site was simultaneously occupied by two citrate molecules (occupancies of 60% and 40%). In the case of 2S4R, the active site was occupied by a citrate molecule which anchors the 2S4R-isomer from its carbamoyl group. The structures of the complexes suggest that the differences in the interactions between the cyclic imide rings and carbamoyl groups of the compounds with residues His110, Trplll, Trp219 and Cys298 account for differences in their inhibitory potencies.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Australie</li>
<li>France</li>
<li>Japon</li>
<li>Suisse</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Darmanin, Connie" sort="Darmanin, Connie" uniqKey="Darmanin C" first="Connie" last="Darmanin">Connie Darmanin</name>
<name sortKey="Hazemann, Isabelle" sort="Hazemann, Isabelle" uniqKey="Hazemann I" first="Isabelle" last="Hazemann">Isabelle Hazemann</name>
<name sortKey="Mitschler, Andre" sort="Mitschler, Andre" uniqKey="Mitschler A" first="Andre" last="Mitschler">Andre Mitschler</name>
<name sortKey="Oka, Mitsuru" sort="Oka, Mitsuru" uniqKey="Oka M" first="Mitsuru" last="Oka">Mitsuru Oka</name>
<name sortKey="Podjarny, Alberto" sort="Podjarny, Alberto" uniqKey="Podjarny A" first="Alberto" last="Podjarny">Alberto Podjarny</name>
<name sortKey="Schulze Briese, Clemens" sort="Schulze Briese, Clemens" uniqKey="Schulze Briese C" first="Clemens" last="Schulze-Briese">Clemens Schulze-Briese</name>
<name sortKey="Tomizaki, Takashi" sort="Tomizaki, Takashi" uniqKey="Tomizaki T" first="Takashi" last="Tomizaki">Takashi Tomizaki</name>
</noCountry>
<country name="Australie">
<noRegion>
<name sortKey="El Kabbani, Ossama" sort="El Kabbani, Ossama" uniqKey="El Kabbani O" first="Ossama" last="El-Kabbani">Ossama El-Kabbani</name>
</noRegion>
</country>
<country name="Japon">
<noRegion>
<name sortKey="El Kabbani, Ossama" sort="El Kabbani, Ossama" uniqKey="El Kabbani O" first="Ossama" last="El-Kabbani">Ossama El-Kabbani</name>
</noRegion>
</country>
<country name="Suisse">
<noRegion>
<name sortKey="El Kabbani, Ossama" sort="El Kabbani, Ossama" uniqKey="El Kabbani O" first="Ossama" last="El-Kabbani">Ossama El-Kabbani</name>
</noRegion>
</country>
<country name="France">
<noRegion>
<name sortKey="El Kabbani, Ossama" sort="El Kabbani, Ossama" uniqKey="El Kabbani O" first="Ossama" last="El-Kabbani">Ossama El-Kabbani</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00AC48 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00AC48 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:05-0124639
   |texte=   High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor fidarestat: Stereospecific interaction between the enzyme and a cyclic imide type inhibitor
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024